TAB Diagnostic

Innovative diabetes office/home solution


(

Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9

BETTER DIAGNOSTICS, BETTER HEALTH
TAB Diagnostics: Fast Facts

Innovative Diabetes office/home diagnostic product to measure Glycated Albumin levels in a shorter time than HbA1c and help the physician to modify the treatment for the patient, reducing the risk of long-term diabetes complications.

BETTER DIAGNOSTICS, BETTER HEALTH
Enormously Problematic

There is a significant problem with delays in T2D therapy adjustment.

Studies have shown that achieving glycemic targets sooner leads to better outcomes and reduces risks of microvascular and macrovascular complications in people with T2D. Despite advances in medication and behavioral treatment in T2D in the past 20 years, the average A1C in the U.S. has not substantially changed in the past decade.


A recent study found that, within survey periods of 2007–2010 and 2011–2014, achievement of individualized glycemic targets declined from 69.8% to 63.8%, and the percentage of individuals with an A1C >9.0% increased from 12.6 to 15.5%

BETTER DIAGNOSTICS, BETTER HEALTH
One Incredible Solution

TAB Diagnostics will solve these problems with five key attributes:

BETTER DIAGNOSTICS, BETTER HEALTH
How It Works

The product line consists of a disposable cassette (and spoid/dropper) and a reusable reader.

The device provides calculated glycation ratio in percent by measuring the concentration of glycated albumin and albumin in the saliva sample.

The albumin test can be carried out at any time of the day (after 30 minutes without food, brushing or gargling) and requires no special dietary supplements before performing the test.

It is designed to be straightforward where one can start the scan within 10 minutes of opening the cassette pouch for accurate test results.

BETTER DIAGNOSTICS, BETTER HEALTH
Traction & Accomplishments

 

Product Development
R&D, pilot production equipment and manufacturing resources are in place. Our platform device and components have undergone significant testing, achieving Korean FDA approval (KFDA) for two readers (Protein/Diabetes/COVID), and, in preparation for FDA submission, we completed a Feasibility Study at University of Maryland and a Pre-Design Verification at Yeong Nam University.

Patents
TAB Diagnostics has an exclusive global IP license along with 27 issued patents covering broad methods and techniques. IP Highlights and Core Patents:

Partnerships
FTI, our R&D partner, developed the manufacturing process for the salivary diagnostic device with their foundry partner NDD, based in Gumi-si, Gyeongsangbuk-do, South Korea.

TAB Diagnostic has established a partnership with Fuzbien Technology Institute (FTI), based in Rockville, MD to provide R&D support for the FET Biosensor technology licensed to TAB Diagnostic. FTI is led by CEO, Dr. Saeyoung Nate Ahn, a FET Subject Matter Expert and inventor of the applicable IP used. FTI as our R&D partner has developed a best in industry manufacturing process with their foundry partner Nano Diagnostics & Devices (NDD) located in the IT-Medical Complex, Gumi, South Korea

BETTER DIAGNOSTICS, BETTER HEALTH
Meet The Team

Troy Barring  FOUNDER AND CEO

  • Served in the U.S. Army as an Armor Officer after graduating from the United States Military Academy at West Point
  • Has held a variety of senior leadership positions in Fortune 500 Companies, achieving stellar results
  • 15+ years of experience in General Management, Sales & Marketing, R&D, Clinical and Operations with P&L’s ranging from $80M-$400M

Sung Pak  CHIEF OPERATING OFFICER

  • Has taken multiple technologies from laboratory concepts to commercial successes, leveraging government, venture-capital, and other funds
  • Pak co-led a $5M Department of Energy project involving three universities, two national labs, and five industrial participants
  • He developed metal- and composite-making 3D printers using funds supported by the DARPA, the Army, and the NSF, totaling more than $4,000,000; the company became the second leading player in the 3D printing industry

Jean Chen, PhD  VICE PRESIDENT REGULATORY, CLINICAL AND QUALITY

  • 25+ years of experience and technical skills in both small and large companies in Clinical Affairs, Quality Engineering, Manufacturing Engineering and Regulatory Affairs
  • Track record of delivering results in challenging situations in critical areas (process, operation, product launch, organization management)
  • Previously served large companies including Baxter Healthcare, B Braun Medical and Edwards Lifesciences, as well as small companies like 3F Therapeutics.

Victor Miranda, MD, MBA  MEDICAL ADVISOR

  • An executive with extensive domestic and international experience in clinical affairs, Phase II, III, IV clinical trials and more
  • Successful track record of domestic and international clinical and marketing management
  • Served as Medical Director for Life Scan (2006-2010), where he directed clinical trials, Investigator-Initiated Studies, and other external investigations conducted worldwide

Dr. Saeyoung Nate Ahn  CHAIRMAN & CEO OF NDD AND FTI

  • Carbon nanotube field effect transistor (FET) Subject Matter Expert and holds nearly over sixty patents on various technologies in the field of physics, biomedical implants, nanotechnology, and manufacturing industries. 
  • 25+ years FET and electron beam research experience leading programs at US Naval Research.
  • Led key nano biomedical science programs for National Nano Science Committee in Korea.

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.


Request Access

N

No updates yet.




%

No backers yet.




Quick Signup TBD

You must have an account to do this!


the startups.com platform

Copyright © 2019 Startups.com. All rights reserved.

Fundable is a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.